| Product Unit Size | Cost | Quantity | Stock |
|---|
CCT-245737 is an inhibitor of checkpoint kinase (CHK) 1. It is 1,000 fold selective for CHK1 over CHK2 and CDK1. It enhances the efficacy of gemcitabine in human tumor xenografts. It also shows potential as a monotherapy in a MYC-driven mouse model of B-cell lymphoma.
| Cas No. | 1489389-18-5 |
|---|---|
| Purity | ≥98% |
| Formula | C16H16F3N7O |
| Formula Wt. | 379.35 |
| IUPAC Name | 5-{[4-{[(2R)-2-Morpholinylmethyl]amino}-5-(trifluoromethyl)-2-pyridinyl]amino}-2-pyrazinecarbonitrile |
| Synonym | CCT-245737, CCT 245737, CCT245737 |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Walton M., Eve P., et al. The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma. Oncotarget. 7(3):2329-42 (2016). PMID: 26295308.